Key result
Atorvastatin trial investigates in-hospital mortality reduction versus placebo in acute aortic dissection.
Why the study?
The effect of statins on the survival of patients with acute aortic dissection has been scarcely investigated, particularly in randomized controlled trials.
Does atorvastatin reduce in-hospital mortality in patients with acute aortic dissection?
RCT (n=384)
Double-blind
1:1 ratio, random-number tables, block size four, stratified by type of AAD
No
Does atorvastatin reduce in-hospital mortality in patients with acute aortic dissection?
This study protocol outlines a randomized controlled trial to evaluate whether atorvastatin reduces in-hospital mortality in patients with acute aortic dissection.
Answers are grounded in this paper and cite their sources.
No practice change for acute aortic dissection; RCT will deliver first randomized data on atorvastatin.
Background: Dyslipidemia and local inflammation at sites of lipid deposition on blood vessel walls have been demonstrated to be risk factors for patients with acute aortic dissection (AAD). Statins have anti-inflammatory and lipid-lowering effects, which suggest that statins may play an important role in prevention and treatment of AAD. Some retrospective studies show that statins can protect patients with aortic dissection. However, the effect of statins on survival of AAD patients have been scarcely investigated, especially in randomized trials. In this study, we will perform a randomized controlled trial (RCT) to evaluate the effect of statins on in-hospital mortality of AAD patients. Methods: A total of 384 subjects diagnosed with AAD in the First Affiliated Hospital of Shantou University Medical College will be recruited. Participants will be randomly divided into atorvastatin-treated or placebo groups. The primary outcome will be the in-hospital mortality. Discussion: This study is designed to verify the safety and efficacy of atorvastatin in patients with AAD. The aim is to provide a new way to improve survival as a complement to conventional drug therapy.Trial registration: Registered by Chinese Clinical Trials Registry (Registration number:ChiCTR1900023515,http://www.chictr.org.cn/edit.aspx?pid=38275&htm=4).Registered 1 June 2019.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted an RCT in Acute aortic dissection (AAD) (n=384). Atorvastatin vs. Placebo was evaluated on In-hospital mortality. Atorvastatin 20 mg daily is being evaluated in a randomized, placebo-controlled trial to determine its efficacy in reducing in-hospital mortality among patients with acute aortic dissection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: